dpp 4 inhibitor glp 1 agonist DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits | Military Medical Research Lesson: A Clinical Overview of

Confused about GLP-1s

The SELECT study enrolled 17,604 individuals aged 45 years or older with existing cardiovascular disease, no T2D, and a BMI exceeding 27 kg/m 2

The LEADER trial with liraglutide reported a reduction in MACE (HR 0.87), while the REWIND trial with dulaglutide demonstrated an HR of 0.88

Glycemic efficacy, weight effects, and safety of once-weekly glucagon-like peptide-1 receptor agonists

Alternately, some individuals may be able to successfully transition to an older generation medication.* Whatever path a member and their prescriber may choose, it is important to continue the lifestyle changes these medications are intended to be an adjunct to

Theres no wrong answer, just what works best for your routine